QSI — Quantum-Si incorporated

QSI (Quantum-Si) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $451,000, impacted by capital sales headwinds.
• Full Year Revenue: $2.4 million, with a gross profit of $1.2 million and a gross margin of 47%.
• Q4 Gross Profit: $122,000, resulting in a gross margin of 27%, affected by a higher proportion of consumable revenue and inventory adjustments.
• Operating Expenses: Q4 GAAP operating expenses were $21.2 million, down from $31.3 million in Q4 2024. Full year GAAP operating expenses were $117.3 million, up from $110.2 million in 2024.
• Cash Position: As of December 31, 2025, QSI had $215.8 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Corporate Priorities for 2025: Focused on accelerating commercial adoption, delivering on innovation, and preserving financial strength.
• Consumable Revenue Growth: The company secured 17 new customers through an expanded instrument acquisition program, which allows labs to use instruments without upfront capital costs.
• Scientific Publications: Five manuscripts submitted in 2025, with three published in early 2026, showcasing the technology's application in clinical proteomics and rapid pathogen detection.
• Proteus Development: The company is prioritizing the launch of the Proteus system, expected by the end of 2026, with a list price set at $425,000. Early feedback indicates strong interest from potential customers.
• Innovation Roadmap: Successful launches of new sequencing kits and ongoing improvements in proteome coverage and sequencing capabilities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be approximately $1 million, primarily from consumables and services, with very modest capital sales.
• Operating Expenses: Anticipated adjusted operating expenses of $98 million or less, reflecting the focus on Proteus development and market readiness.
• Cash Usage: Expected total cash usage of $93 million or less for 2026, with a strong cash position to support operations into 2028.

4. Bad News, Challenges, or Points of Concern

• Capital Sales Headwinds: Continued delays in NIH funding and uncertainties regarding the NIH budget have impacted capital expenditures, affecting sales of the Platinum Pro instruments.
• Limited Capital Sales: The company expects very few new placements of the Platinum Pro instruments in 2026 as customers await the Proteus launch.
• Gross Margin Pressure: The shift towards consumable revenue, which typically has lower margins than equipment sales, may lead to lower overall gross margins in 2026 compared to previous years.

5. Notable Q&A Insights

• Consumable Trends: Management indicated a projected increase of over 25% in consumable kit utilization among customers in 2026, despite limited capital sales.
• Customer Feedback: Customers are hesitant to invest in current technology when a new product (Proteus) is on the horizon, leading to a focus on consumables and service revenue.
• Launch Risks: The primary risks to the Proteus launch revolve around hardware integration and manufacturing quality rather than technical innovation, which has already been achieved.
• Market Dynamics: The company is monitoring NIH funding developments closely, but has not received specific feedback from customers regarding funding timelines.

This summary encapsulates the key elements discussed during the earnings call, providing a clear overview of QSI's financial performance, strategic direction, and outlook for the future.